United Therapeutics Corporation Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
United Therapeutics Corporation (UTHR) reported Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount · last filed 2025-02-26
- United Therapeutics Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2024 was $0.00.
- United Therapeutics Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2023 was $0.00.
- United Therapeutics Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2022 was $0.00.
- United Therapeutics Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2021 was $0.00.
| Period end | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |